E
Fulgent Genetics, Inc.
FLGT
$18.59
$0.693.86%
E
Sell
5/7/2024Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to E+ from D on 5/7/2024 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 51.34% from $14.93M to $7.27M, total revenue declined 8.54% from $70.51M to $64.49M, and total capital declined 0.58% from $1.15B to $1.14B.
Fulgent Genetics, Inc. (FLGT) was downgraded to E+ from D on 5/7/2024 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 51.34% from $14.93M to $7.27M, total revenue declined 8.54% from $70.51M to $64.49M, and total capital declined 0.58% from $1.15B to $1.14B.
D
Sell
10/12/2023Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to D from D+ on 10/12/2023 due to a decline in the volatility index, total return index and efficiency index. Total capital declined 1.8% from $1.31B to $1.28B.
Fulgent Genetics, Inc. (FLGT) was downgraded to D from D+ on 10/12/2023 due to a decline in the volatility index, total return index and efficiency index. Total capital declined 1.8% from $1.31B to $1.28B.
D
Sell
5/8/2023Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to D+ from C- on 5/8/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 123.81% from $33.21M to -$7.91M, total revenue declined 2.27% from $67.7M to $66.17M, and total capital declined 0.3% from $1.31B to $1.3B.
Fulgent Genetics, Inc. (FLGT) was downgraded to D+ from C- on 5/8/2023 due to a significant decline in the valuation index, efficiency index and growth index. Operating cash flow declined 123.81% from $33.21M to -$7.91M, total revenue declined 2.27% from $67.7M to $66.17M, and total capital declined 0.3% from $1.31B to $1.3B.
C
Hold
3/1/2023Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C- from C on 3/1/2023 due to a substantial decline in the growth index, total return index and valuation index. EBIT declined 6,068.93% from $457 to -$27.28M, earnings per share declined from $0.057 to -$0.8099, and total revenue declined 35.92% from $105.66M to $67.7M.
Fulgent Genetics, Inc. (FLGT) was downgraded to C- from C on 3/1/2023 due to a substantial decline in the growth index, total return index and valuation index. EBIT declined 6,068.93% from $457 to -$27.28M, earnings per share declined from $0.057 to -$0.8099, and total revenue declined 35.92% from $105.66M to $67.7M.
C
Hold
10/6/2022Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C from C+ on 10/6/2022 due to a substantial decline in the growth index, volatility index and total return index. Operating cash flow declined 94.09% from $188.41M to $11.13M, earnings per share declined from $4.93 to $0.37, and EBIT declined 92.23% from $201.93M to $15.69M.
Fulgent Genetics, Inc. (FLGT) was downgraded to C from C+ on 10/6/2022 due to a substantial decline in the growth index, volatility index and total return index. Operating cash flow declined 94.09% from $188.41M to $11.13M, earnings per share declined from $4.93 to $0.37, and EBIT declined 92.23% from $201.93M to $15.69M.
C
Hold
4/18/2022Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to C+ from C on 4/18/2022 due to an increase in the total return index.
Fulgent Genetics, Inc. (FLGT) was upgraded to C+ from C on 4/18/2022 due to an increase in the total return index.
C
Hold
3/21/2022Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C from C+ on 3/21/2022 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 49.35% from $152.2M to $77.09M, earnings per share declined from $3.93 to $3.3451, and EBIT declined 4.59% from $161.47M to $154.06M.
Fulgent Genetics, Inc. (FLGT) was downgraded to C from C+ on 3/21/2022 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 49.35% from $152.2M to $77.09M, earnings per share declined from $3.93 to $3.3451, and EBIT declined 4.59% from $161.47M to $154.06M.
C
Hold
12/7/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B on 12/7/2021 due to a substantial decline in the total return index.
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B on 12/7/2021 due to a substantial decline in the total return index.
B
Buy
11/24/2021Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 11/24/2021 due to a major increase in the total return index and volatility index.
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 11/24/2021 due to a major increase in the total return index and volatility index.
B
Buy
11/10/2021Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C+ on 11/10/2021 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 99.97% from $76.11M to $152.2M, EBIT increased 60.51% from $99.23M to $159.27M, and net income increased 53.51% from $79.81M to $122.52M.
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C+ on 11/10/2021 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 99.97% from $76.11M to $152.2M, EBIT increased 60.51% from $99.23M to $159.27M, and net income increased 53.51% from $79.81M to $122.52M.
C
Hold
10/18/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B- on 10/18/2021 due to a significant decline in the total return index.
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B- on 10/18/2021 due to a significant decline in the total return index.
B
Buy
10/1/2021Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C+ on 10/1/2021 due to a substantial increase in the total return index, efficiency index and valuation index. Total capital increased 15.45% from $817.55M to $943.89M.
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C+ on 10/1/2021 due to a substantial increase in the total return index, efficiency index and valuation index. Total capital increased 15.45% from $817.55M to $943.89M.
C
Hold
5/10/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B- on 5/10/2021 due to a decline in the growth index, total return index and volatility index.
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B- on 5/10/2021 due to a decline in the growth index, total return index and volatility index.
B
Buy
4/26/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 4/26/2021 due to a substantial decline in the total return index and volatility index.
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 4/26/2021 due to a substantial decline in the total return index and volatility index.
B
Buy
4/9/2021Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 4/9/2021 due to a noticeable increase in the total return index and valuation index.
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 4/9/2021 due to a noticeable increase in the total return index and valuation index.
B
Buy
3/25/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 3/25/2021 due to a decline in the volatility index, total return index and valuation index.
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 3/25/2021 due to a decline in the volatility index, total return index and valuation index.
B
Buy
3/10/2021Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 3/10/2021 due to a significant increase in the valuation index, growth index and volatility index. Operating cash flow increased 1,325.98% from $9.42M to $134.26M, EBIT increased 263.91% from $63.52M to $231.17M, and earnings per share increased from $1.98 to $6.1614.
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 3/10/2021 due to a significant increase in the valuation index, growth index and volatility index. Operating cash flow increased 1,325.98% from $9.42M to $134.26M, EBIT increased 263.91% from $63.52M to $231.17M, and earnings per share increased from $1.98 to $6.1614.
B
Buy
2/25/2021Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C+ on 2/25/2021 due to an increase in the total return index and volatility index.
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C+ on 2/25/2021 due to an increase in the total return index and volatility index.
C
Hold
2/4/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B- on 2/4/2021 due to a large decline in the valuation index.
Fulgent Genetics, Inc. (FLGT) was downgraded to C+ from B- on 2/4/2021 due to a large decline in the valuation index.
B
Buy
1/12/2021Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 1/12/2021 due to a large decline in the total return index and valuation index.
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 1/12/2021 due to a large decline in the total return index and valuation index.
B
Buy
12/28/2020Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 12/28/2020 due to a large increase in the total return index and valuation index.
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 12/28/2020 due to a large increase in the total return index and valuation index.
B
Buy
12/11/2020Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 12/11/2020 due to a large decline in the total return index and valuation index.
Fulgent Genetics, Inc. (FLGT) was downgraded to B- from B on 12/11/2020 due to a large decline in the total return index and valuation index.
B
Buy
11/23/2020Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 11/23/2020 due to an increase in the total return index and volatility index.
Fulgent Genetics, Inc. (FLGT) was upgraded to B from B- on 11/23/2020 due to an increase in the total return index and volatility index.
B
Buy
11/10/2020Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C on 11/10/2020 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 2,306.17% from $2.64M to $63.52M, earnings per share increased from $0.14 to $1.98, and net income increased 1,304.34% from $3.32M to $46.64M.
Fulgent Genetics, Inc. (FLGT) was upgraded to B- from C on 11/10/2020 due to a significant increase in the valuation index, efficiency index and growth index. EBIT increased 2,306.17% from $2.64M to $63.52M, earnings per share increased from $0.14 to $1.98, and net income increased 1,304.34% from $3.32M to $46.64M.
C
Hold
8/7/2020Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to C from D on 8/7/2020 due to a significant increase in the growth index, efficiency index and total return index. Net income increased 269.79% from -$1.96M to $3.32M, earnings per share increased from -$0.0907 to $0.14, and EBIT increased 237.93% from -$1.91M to $2.64M.
Fulgent Genetics, Inc. (FLGT) was upgraded to C from D on 8/7/2020 due to a significant increase in the growth index, efficiency index and total return index. Net income increased 269.79% from -$1.96M to $3.32M, earnings per share increased from -$0.0907 to $0.14, and EBIT increased 237.93% from -$1.91M to $2.64M.
D
Sell
5/1/2020Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to D from D+ on 5/1/2020 due to a substantial decline in the efficiency index and valuation index.
Fulgent Genetics, Inc. (FLGT) was downgraded to D from D+ on 5/1/2020 due to a substantial decline in the efficiency index and valuation index.
D
Sell
4/16/2020Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to D+ from D on 4/16/2020 due to an increase in the total return index.
Fulgent Genetics, Inc. (FLGT) was upgraded to D+ from D on 4/16/2020 due to an increase in the total return index.
D
Sell
3/20/2020Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to D from D+ on 3/20/2020 due to a noticeable decline in the total return index.
Fulgent Genetics, Inc. (FLGT) was downgraded to D from D+ on 3/20/2020 due to a noticeable decline in the total return index.
D
Sell
3/16/2020Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to D+ from C- on 3/16/2020 due to a major decline in the growth index. EBIT declined 127.1% from $1.51M to -$409, earnings per share declined from $0.079 to -$0.0148, and operating cash flow declined 102.97% from $3.9M to -$116.
Fulgent Genetics, Inc. (FLGT) was downgraded to D+ from C- on 3/16/2020 due to a major decline in the growth index. EBIT declined 127.1% from $1.51M to -$409, earnings per share declined from $0.079 to -$0.0148, and operating cash flow declined 102.97% from $3.9M to -$116.
C
Hold
9/16/2019Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to C- from D+ on 9/16/2019 due to a noticeable increase in the total return index, growth index and efficiency index. Net income increased 117.35% from -$1.91M to $331, earnings per share increased from -$0.1047 to $0.018, and EBIT increased 116.18% from -$1.82M to $295.
Fulgent Genetics, Inc. (FLGT) was upgraded to C- from D+ on 9/16/2019 due to a noticeable increase in the total return index, growth index and efficiency index. Net income increased 117.35% from -$1.91M to $331, earnings per share increased from -$0.1047 to $0.018, and EBIT increased 116.18% from -$1.82M to $295.
D
Sell
5/17/2019Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to D+ from D on 5/17/2019 due to a major increase in the total return index, volatility index and growth index. Operating cash flow increased 35.6% from $778 to $1.06M, and earnings per share increased from -$0.1133 to -$0.1047.
Fulgent Genetics, Inc. (FLGT) was upgraded to D+ from D on 5/17/2019 due to a major increase in the total return index, volatility index and growth index. Operating cash flow increased 35.6% from $778 to $1.06M, and earnings per share increased from -$0.1133 to -$0.1047.
D
Sell
10/2/2017Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to D from D- on 10/2/2017 due to a major increase in the efficiency index and growth index. Operating cash flow increased 93.07% from $707 to $1.37M, and total capital increased 0.79% from $55.3M to $55.73M.
Fulgent Genetics, Inc. (FLGT) was upgraded to D from D- on 10/2/2017 due to a major increase in the efficiency index and growth index. Operating cash flow increased 93.07% from $707 to $1.37M, and total capital increased 0.79% from $55.3M to $55.73M.
D
Sell
6/1/2017Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to D- from E on 6/1/2017 due to an increase in the valuation index.
Fulgent Genetics, Inc. (FLGT) was upgraded to D- from E on 6/1/2017 due to an increase in the valuation index.
E
Sell
5/17/2017Downgrade
Fulgent Genetics, Inc. (FLGT) was downgraded to E from E+ on 5/17/2017 due to a substantial decline in the volatility index, total return index and efficiency index. Net income declined 71.46% from $813 to $232.
Fulgent Genetics, Inc. (FLGT) was downgraded to E from E+ on 5/17/2017 due to a substantial decline in the volatility index, total return index and efficiency index. Net income declined 71.46% from $813 to $232.
E
Sell
3/1/2017Upgraded
Fulgent Genetics, Inc. (FLGT) was upgraded to E+ from E on 3/1/2017 due to a major increase in the total return index and solvency index.
Fulgent Genetics, Inc. (FLGT) was upgraded to E+ from E on 3/1/2017 due to a major increase in the total return index and solvency index.
E
Sell
12/22/2016None
Fulgent Genetics, Inc. (FLGT) was downgraded to E from U on 12/22/2016.
Fulgent Genetics, Inc. (FLGT) was downgraded to E from U on 12/22/2016.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
